Pricing adjustments for CAR-T therapies likely to take place in 2018, says analyst
Despite the promising findings that the currently approved chimeric antigen receptor T-cell (CAR-T) immuno-oncology (I-O) therapies – Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) – are beneficial, practical challenges associated with their pricing and reimbursement remain.
New research from analytics company GlobalData points out that, currently, Novartis’ (NOVN: VX) Kymriah and Gilead/Kite Pharma/Gilead Sciences’ (Nasdaq: GILD) Yescarta are the only CAR-T cell therapies available in the US market. The labels for both drugs contain boxed warnings for severe adverse events - cytokine release syndrome as well as neurologic toxicities.
Upon launch, Kymriah (August 2017) and Yescarta (October 2017) were priced at $475,000 and $373,000 per treatment, respectively, placing these among the highest-priced drugs on the oncology market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze